Document:

Stock Purchase Agreement - Ablaris Therapeutics, Inc.

 Exhibit 10.2 
 FORM OF SERIES A PREFERRED STOCK PURCHASE AGREEMENT 
 THIS SERIES A
PREFERRED STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of the     th day of January, 2011 by and among Ablaris Therapeutics Inc., a Delaware corporation (the “Company”), the
investor listed on Exhibit A attached to this Agreement (the “Purchaser”). 
 The parties hereby agree
as follows: 
 1. Purchase and Sale of Preferred Stock. 

1.1 Sale and Issuance of Series A Preferred Stock. 
 (a) The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Initial Closing (as defined below) the Amended and Restated Certificate of Incorporation in the
form of Exhibit B attached to this Agreement (the “Restated Certificate”). 
 (b) Subject to the
terms and conditions of this Agreement, each Purchaser agrees to purchase at the Closing and the Company agrees to sell and issue to the Purchaser at the Closing that number of shares of Series A Preferred Stock set forth opposite each
Purchaser’s name on Exhibit A, at a purchase price of $1.00 per share. The shares of Series A Preferred Stock issued to the Purchasers pursuant to this Agreement (including any shares issued at the Initial Closing (the
“Initial Shares”) and any Additional Shares, as defined below) shall be referred to in this Agreement as the “Shares.” 
 1.2 Closing; Delivery. 
 (a) The purchase and sale of the Initial Shares
shall take place remotely via the exchange of documents and signatures, at 10:00 a.m., on January     , 2010, or at such other time and place as the Company and the Purchasers mutually agree upon, orally or in writing
(which time and place are designated as the “Initial Closing”). In the event there is more than one closing, the term “Closing” shall apply to each such closing unless otherwise specified. 

(b) At each Closing, the Company shall deliver to each Purchaser a certificate representing the Shares being purchased by such Purchaser
at such Closing against payment of the purchase price therefor by check payable to the Company, by wire transfer to a bank account designated by the Company, by cancellation or conversion of indebtedness of the Company to Purchaser, or by any
combination of such methods. 
 1.3 Sale of Additional Shares of Preferred Stock. After the Initial Closing, the Company
may sell, on the same terms and conditions as those contained in this Agreement, up to the balance of additional shares of Series A Preferred Stock (the “Additional Shares”), to one or more purchasers (the “Additional
Purchasers”), provided that (i) such subsequent sale is consummated prior to 90 days after the Initial Closing, (ii) each Additional Purchaser shall become a party to the Transaction Agreements, (as defined below), by executing

 
and delivering a counterpart signature page to each of the Transaction Agreements, (iii) each of the Purchasers is given prior notice of the terms and timing of such Additional Closing.
Exhibit A to this Agreement shall be updated to reflect the number of Additional Shares purchased at each such Closing and the parties purchasing such Additional Shares. 

1.4 Use of Proceeds. In accordance with the directions of the Company’s Board of Directors, the Company will use the
proceeds from the sale of the Shares for product development and other general corporate purposes. 
 1.5 Defined Terms Used
in this Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below. 

“Affiliate” means, with respect to any specified Person, any other Person who or which, directly or indirectly,
controls, is controlled by, or is under common control with such specified Person, including, without limitation, any partner, officer, director, member or employee of such Person and any venture capital fund now or hereafter existing that is
controlled by or under common control with one or more general partners or managing members of, or shares the same management company with, such Person. 
 “Code” means the Internal Revenue Code of 1986, as amended. 

“Company Intellectual Property” means all patents, patent applications, trademarks, trademark applications, service
marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of
any of the foregoing, licenses in to and under any of the foregoing, in any and all such cases that are owned by the Company or used by the Company in the conduct of the Company’s business as now conducted and as presently proposed to be
conducted. 
 “Registration Rights Agreement” means the agreement between the Company and the Purchasers dated
as of the date of the Initial Closing, in the form of Exhibit C attached to this Agreement. 
 “Knowledge,”
including the phrase “to the Company’s knowledge,” shall mean the actual knowledge after reasonable investigation of the Company. 
 “Material Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, or results of operations of
the Company. 
 “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 “Purchaser” means each of the Purchasers who is initially a party to this
Agreement and any Additional Purchaser who becomes a party to this Agreement at a subsequent Closing under Section 1.3. 

 “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. 
 “Series A Preferred Stock” means the Series A Preferred Stock
of the Company issued under the terms of the Restated Certificate. 
 “Shares” means the Initial Shares issued
at the Initial Closing and any Additional Shares issued at a subsequent Closing under Section 1.3. 

“Transaction Agreements” means this Agreement and the Registration Rights Agreement. 

2. Representations and Warranties of the Company. The Company hereby represents and warrants to each Purchaser as follows.

 2.1 Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified to
transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect. 
 2.2 Capitalization. All of the outstanding securities of the Company have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state
securities laws. The authorized capital of the Company consists, immediately prior to the Initial Closing, of: 
 (a)
20,000,000 shares of Common Stock, 10,000,000 shares of which are issued and outstanding immediately prior to the Initial Closing. 
 (b) 10,000,000 shares of Preferred Stock, 4,000,000 of which have been designated Series A Preferred Stock, none of which are issued and outstanding immediately prior to the Initial Closing. The
rights, privileges and preferences of the Preferred Stock are as stated in the Restated Certificate and as provided by the general corporation law of the jurisdiction of the Company’s incorporation. 

(c) Except for (A) the conversion privileges of the Shares to be issued under this Agreement, and (B) the rights provided in
the Registration Rights Agreement, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the
Company any shares of Common Stock or Series A Preferred Stock, or any securities convertible into or exchangeable for shares of Common Stock or Series A Preferred Stock. 
 (d) The Company is under no obligation, including, but not limited to, under its stock purchase agreements or stock option documents, to accelerate vesting (or lapse a repurchase right) or make other
changes in the vesting provisions or other terms of any agreement or understanding upon the occurrence of any event or combination of events. 

 2.3 Subsidiaries. The Company does not currently own or control, directly or
indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. 
 2.4 Authorization. All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to authorize the Company to enter into the Transaction Agreements,
and to issue the Shares at the Closing and the Common Stock issuable upon conversion of the Shares, has been taken or will be taken prior to the Closing. All action on the part of the officers of the Company necessary for the execution and delivery
of the Transaction Agreements, the performance of all obligations of the Company under the Transaction Agreements to be performed as of the Closing, and the issuance and delivery of the Shares has been taken or will be taken prior to the Closing.
The Transaction Agreements, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration Rights Agreement may be limited by applicable federal or state securities
laws. 
 2.5 Valid Issuance of Shares. The Shares, when issued, sold and delivered in accordance with the terms and for
the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable state and federal securities
laws and liens or encumbrances created by or imposed by a Purchaser. Assuming the accuracy of the representations of the Purchasers in Section 3 of this Agreement and subject to the filings described in Section 2.6(ii) below,
the Shares will be issued in compliance with all applicable federal and state securities laws. The Common Stock issuable upon conversion of the Shares has been duly reserved for issuance, and upon issuance in accordance with the terms of the
Restated Certificate, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable federal and state securities laws and liens or
encumbrances created by or imposed by a Purchaser. 
 2.6 Governmental Consents and Filings. Assuming the accuracy of
the representations made by the Purchasers in Section 3 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental
authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for (i) the filing of the Restated Certificate, which will have been filed as of the Initial
Closing, and (ii) filings pursuant to Regulation D of the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner. 

2.7 Litigation. There is no action, suit, proceeding or investigation by or against the Company pending or which the Company
intends to initiate. 

 2.8 Intellectual Property. The Company possesses, or will possess at Closing,
sufficient and enforceable legal rights to such Company Intellectual Property as necessary for the operation of the Company’s business as now conducted and as presently proposed to be conducted and possesses sufficient and enforceable legal
rights to all Company Intellectual Property licensed to the Company as necessary for the operation of the Company’s business as now conducted and as presently proposed to be conducted, and without any known conflict with, or infringement of,
the rights of others. The Company has not received any written communications alleging that the Company has violated or, by conducting the Company’s business, would violate any of the patents, trademarks, service marks, tradenames, copyrights,
trade secrets, mask works or other proprietary or intellectual property rights or processes of any other Person. To the Company’s knowledge, it will not be necessary to use any inventions of any of its employees or consultants (or persons it
currently intends to hire) made prior to their employment by the Company. Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related to the Company’s business as now conducted and
as presently proposed to be conducted. 
 2.9 Compliance with Other Instruments. The Company is not in violation or
default of any provisions of its Restated Certificate or Bylaws, or, to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect.

 2.10 Agreements; Actions. 
 (a) Except for the Transaction Agreements and the M.D. Anderson License, there are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by
which it is bound that involve material obligations (contingent or otherwise) of, or payments to, the Company. 
 (b) The
Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or (iii) made any loans or
advances to any Person. 
 2.11 Rights of Registration. Except as provided in the Registration Rights Agreement, the
Company is not under any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. 

2.12 Absence of Liens. The property and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens,
loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership
or use of such property or assets. 
 2.13 Disclosure. The Company has made available to the Purchasers all the
information reasonably available to the Company that the Purchasers have requested for deciding whether to acquire the Shares. To the Company’s knowledge, no representation or 

 
warranty of the Company contained in this Agreement, and no certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material fact or omits to
state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. It is understood that this representation is qualified by the fact that the Company
has not delivered to the Purchasers, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities. 

3. Representations and Warranties of the Purchasers. Each Purchaser hereby represents and warrants to the Company, severally and
not jointly, that: 
 3.1 Authorization. The Purchaser has full power and authority to enter into the Transaction
Agreements. The Transaction Agreements to which such Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser, enforceable in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the
availability of specific performance, injunctive relief, or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Registration Rights Agreement may be limited by applicable federal or state securities
laws. 
 3.2 Purchase Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the
Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing
this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with
respect to any of the Shares. The Purchaser has not been formed for the specific purpose of acquiring the Shares. 
 3.3
Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an
opportunity to review the Company’s facilities. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Purchasers to rely thereon.

 3.4 Restricted Securities. The Purchaser understands that the Shares have not been, and will not be, registered under
the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s
representations as expressed herein. The Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Shares
indefinitely unless they are registered with the 

 
Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the
Company has no obligation to register or qualify the Shares, or the Common Stock into which it may be converted, for resale except as set forth in the Registration Rights Agreement. The Purchaser further acknowledges that if an exemption from
registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company which are outside of
the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. 
 3.5 No Public
Market. The Purchaser understands that no public market now exists for the Shares, and that the Company has made no assurances that a public market will ever exist for the Shares. 

3.6 Legends. The Purchaser understands that the Shares and any securities issued in respect of or exchange for the Shares, may
bear one or all of the following legends: 
 (a) “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR
AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 
 (b) Any legend set forth in, or required by, the other Transaction Agreements and any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented
by the certificate so legended. 
 3.7 Accredited Investor. The Purchaser is an accredited investor as defined in Rule
501(a) of Regulation D promulgated under the Securities Act. 
 3.8 Foreign Investors. If the Purchaser is not a United
States person (as defined by Section 7701(a)(30) of the Code), such Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares
or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents
that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. Such Purchaser’s subscription and payment for and
continued beneficial ownership of the Shares will not violate any applicable securities or other laws of the Purchaser’s jurisdiction. 
 3.9 No General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including through a broker or
finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the Shares. 

 3.10 Exculpation Among Purchasers. Each Purchaser acknowledges that it is not
relying upon any Person, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. Each Purchaser agrees that no Purchaser nor the respective controlling Persons, officers, directors,
partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Shares. 

3.11 Residence. If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the address of the
Purchaser set forth on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address or
addresses of the Purchaser set forth on Exhibit A. 
 4. Conditions to the Purchasers’ Obligations at
Closing. The obligations of each Purchaser to purchase Shares at the Initial Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived: 

4.1 Representations and Warranties; Performance. The representations and warranties of the Company contained in
Section 2 shall be true and correct in all material respects as of such Closing, except that any such representations and warranties shall be true and correct in all respects where such representation and warranty is qualified with
respect to materiality. Performance. The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Company on or before
such Closing. 
 4.2 Transaction Agreements. The Company and each Purchaser (other than the Purchaser relying upon this
condition to excuse such Purchaser’s performance hereunder) and the other stockholders of the Company named as parties thereto shall have executed and delivered the Transaction Agreements. 

4.3 Restated Certificate. The Company shall have filed the Restated Certificate with the Secretary of State of Delaware on or
prior to the Closing, which shall continue to be in full force and effect as of the Closing. 
 4.4 M.D. Anderson
License. The Patent and Technology License by and between the Board of Regents of the University of Texas System, on behalf of the University of Texas M. D. Anderson Cancer Center and Arrowhead Research Corporation, shall have been fully
executed and delivered to the Company (the “M.D. Anderson License”). 

 5. Conditions of the Company’s Obligations at Closing. The obligations of the
Company to sell Shares to the Purchasers at the Initial Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived: 

5.1 Representations and Warranties; Performance. The representations and warranties of each Purchaser contained in
Section 3 shall be true and correct in all material respects as of such Closing. The Purchasers shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to
be performed or complied with by them on or before such Closing. 
 5.2 Transaction Agreements. The each Purchaser and
the other stockholders of the Company named as parties thereto shall have executed and delivered the Transaction Agreements. 

5.3 M.D. Anderson License. The M. D. Anderson license shall have been fully executed and delivered to the Company. 

6. Miscellaneous. 
 6.1 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement. 
 6.2 Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of California, regardless of the laws that might otherwise govern under applicable principles of conflicts of law. 
 6.3 Counterparts; Facsimile. This Agreement may be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 6.4 Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent
during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one
(1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature
page or Exhibit A, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section 6.6. If notice is given to the Company, a copy shall also be sent to
Goodwin Procter LLP, Three Embarcadero Center, 24th Floor,
San Francisco, CA 94111 Attn: Ryan Murr. 
 6.5 Amendments and Waivers. Except as set forth in Section 1.3
of this Agreement, any term of this Agreement may be amended, terminated or waived only with the written consent of the Company and (i) the holders of at least a majority of the then-outstanding Shares or (ii) for an amendment, termination
or waiver effected prior to the Initial Closing, Purchasers obligated to purchase a majority of the Shares to be issued at the Initial 

 
Closing. Any amendment or waiver effected in accordance with this Section 6.5 shall be binding upon the Purchasers and each transferee of the Shares (or the Common Stock issuable upon
conversion thereof), each future holder of all such securities, and the Company. 
 6.6 Severability. The invalidity or
unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 
 6.7
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of
such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach
or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver
on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise
afforded to any party, shall be cumulative and not alternative. 
 6.8 Entire Agreement. This Agreement (including the
Exhibits hereto), the Restated Certificate and the other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement
relating to the subject matter hereof existing between the parties are expressly canceled. 
 6.9 Dispute Resolution.
Any unresolved controversy or claim arising out of or relating to this Agreement, except as (i) otherwise provided in this Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights
for which a provisional remedy or equitable relief is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential
arbitrators have been proposed by the American Arbitration Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the
AAA. The arbitration shall take place in Pasadena, California, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof.
There shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all
party witnesses and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the California Code of Civil Procedure, the arbitrator shall be required to
provide in writing to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. The prevailing party shall be entitled
to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in
the U.S. District Court for the Central District of California or any court of the State of California having subject matter jurisdiction. 

 IN WITNESS WHEREOF, the parties have executed this Series A Preferred Stock Purchase
Agreement as of the date first written above. 
  

			
	COMPANY:
		
	By:	 	  

		
	Name:	 	  

		 	(print)
		
	Title:	 	  

	
	Address:

 IN WITNESS WHEREOF, the parties have executed this Series A Preferred Stock Purchase Agreement as of
the date first written above. 
  

					
	PURCHASERS:
	
	  

	(Print Name of Purchaser)
		
	By:	 	
 

					
		
	No. Shares Purchased:	 	
 

					
		
	Name:	 	  

	(print)
		
	Title:	 	  

		
	Address:	 	  

	
	  

		
	Telephone:	 	  

		
	Email:	 	  

[SIGNATURE PAGE FOR PURCHASE AGREEMENT]Master Services Agreement

 Exhibit 10.2 
 MASTER SERVICES AGREEMENT 
 This Master Services Agreement
(“Agreement”) is made between Sunesis Pharmaceuticals, Inc. which has a place of business at 341 Oyster Point Boulevard, South San Francisco, California 94080 (hereinafter “Sponsor”), and Quintiles, Inc. a North Carolina
corporation having a place of business at 10245 Hickman Mills Drive, Kansas City, MO 64137 (hereinafter “Quintiles”). When signed by both parties, this Agreement will set forth the terms and conditions under which Quintiles agrees to
provide certain services to Sponsor as set forth herein. 
 Recitals: 

A. Sponsor is in the business of drug discovery, research and development for various pharmaceutical products. Quintiles
is in the business of providing drug development and manufacturing services, clinical trial services, and other services for the pharmaceutical, medical device and biotechnology industries. 

B. Sponsor and Quintiles desire to enter into this Agreement to provide the terms and conditions upon which Sponsor may
engage Quintiles from time-to-time to provide services for individual studies or projects by executing individual Work Orders (as defined below) specifying the details of the services and the related terms and conditions. 

Agreement: 
  

	1.0	 Scope of the Agreement; Work Orders; Nature of Services; Transfer of Obligations. 

 

	 	1.1	 Scope of Agreement. As a “master” form of contract, this Agreement allows the parties to contract for multiple projects through the
issuance of multiple Work Orders (as discussed in Section 1.2 below), without having to re-negotiate the basic terms and conditions contained herein. This Agreement covers the provision of services by Quintiles and Quintiles’ corporate
affiliates (see Section 16.1) and, accordingly, this Agreement represents a vehicle by which Sponsor can efficiently contract with Quintiles and its corporate affiliates for a broad range of specific services. 

 

	 	1.2	 Work Orders. The specific details of each project under this Agreement (each “Project”) shall be separately negotiated and
specified in writing on terms and in a form acceptable to the parties (each such writing, a “Work Order”). A sample Work Order is attached hereto as Exhibit A. Each Work Order will include, without limitations, the scope of work,
timeline(s), and budget and payment schedule. Each Work Order shall be subject to all of the terms and conditions of this Agreement, including (when applicable) the terms and conditions set forth in the quality requirement agreement to be completed
by the parties which will be made part of and attached to this Agreement (the “Quality Agreement”), in addition to the specific details set forth in the Work Order. 

 

	 	1.3	 Integration; Precedence. Any Work Order or Change Order (as defined in Section 4.0 below) and other exhibits issued and executed
pursuant to this Agreement will be made part hereof and incorporated herein by reference. To the extent any 

  
 1 

	 	 
terms or provisions of a Work Order or Change Order conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control, except to the extent that
the applicable Work Order or Change Order expressly and specifically states an intent to supersede the Agreement on a specific matter. 

  

	 	1.4	 Nature of Services. The services covered by this Agreement may include expert consultation, clinical trial services, statistical programming
and analysis, clerical, project management, central laboratory services, preclinical services, pharmaceutical sciences services, and related data processing, data management and regulatory services, and other research and development services
requested by Sponsor and agreed to by Quintiles as set forth in the relevant Work Order (collectively, the “Services”). 

  

	 	1.5	 Transfer of Obligations. Quintiles and Sponsor, where appropriate, shall cooperate in the completion of a Transfer of Obligations Form in
conjunction with the relevant Work Order. Any responsibilities not specifically transferred in the Transfer of Obligations Form shall remain the regulatory responsibility of Sponsor. The Transfer of Obligations Form will be filed with the Food and
Drug Administration (“FDA”) by Sponsor where appropriate, or as required by law or regulation. 

  

	2.0	 Payment of Fees and Expenses. Sponsor will pay Quintiles for fees, expenses and pass-through costs in accordance with the budget and payment
schedule contained in each Work Order. Sponsor agrees that the budget and payment schedule for each Work Order will be structured in an effort to maintain cash neutrality for Quintiles (with respect to the payment of professional fees, pass-through
costs and otherwise). Unless otherwise agreed in a particular Work Order, the following shall apply: (a) Quintiles will invoice Sponsor monthly for the fees, expenses and pass-through costs incurred in performing the Services; and,
(b) Sponsor shall pay each invoice within thirty (30) days of receipt of the invoice. If any portion of an invoice is disputed, then Sponsor shall pay the undisputed amounts as set forth in the preceding sentence and the parties shall use
good faith efforts to reconcile the disputed amount as soon as practicable. 

  

	3.0	 Term. This Agreement shall commence on the date it has been signed by all parties and shall continue for a period of five (5) years from
the date of execution, unless otherwise earlier terminated by either party in accordance with Section 15 below. 

  

	4.0	 Change Orders. Any change in the details of a Work Order or the assumptions upon which the Work Order is based (including, but not limited
to, changes in an agreed starting date for a Project or suspension of the Project by Sponsor) may require changes in the budget and/or timelines, and shall require a written amendment to the Work Order (a “Change Order”). Each Change Order
shall detail the requested changes to the applicable task, responsibility, duty, budget, timeline or other matter. The Change Order will become effective upon the execution of the Change Order by both parties, and the parties will agree upon a
reasonable period of time within which Quintiles shall implement the changes. Both parties agree to act in good faith and promptly when considering a Change Order requested by the other party. Without limiting the foregoing, Sponsor agrees that it
will not unreasonably withhold approval of a Change Order, if the 

  
 2 

	 	 
proposed changes in budgets or timelines result from, among other appropriate reasons, forces outside the reasonable control of Quintiles or Sponsor’s changes in the assumptions upon which
the initial budget or timelines were based, including, but not limited to, the assumptions set forth in the budget or timelines. Quintiles reserves the right to postpone effecting material changes in the Project’s scope until such time as the
parties agree to and execute the corresponding Change Order. For any Change Order that affects the scope of the regulatory obligations that have been transferred to Quintiles, Quintiles and Sponsor shall execute a corresponding amendment to the
Transfer of Obligations Form. Sponsor shall file such amendment where appropriate, or as required by law or regulation. 

  

	5.0	 Confidentiality. 

  

	 	5.1	 Sponsor Confidential Information. It is understood that during the course of this Agreement, Quintiles and its employees may be exposed to
data and information that are confidential and proprietary to Sponsor. All such data and information (hereinafter “Sponsor Confidential Information”) written or verbal, tangible or intangible, made available, disclosed, or otherwise made
known to Quintiles and its employees as a result of Services under this Agreement shall be considered confidential and shall be considered the sole property of Sponsor. 

 

	 	5.2	 Quintiles Confidential Information. All information regarding Quintiles’ operations, methods, and pricing and all Quintiles’
Property (as defined in Section 6.2 below), disclosed by Quintiles to Sponsor in connection with this Agreement is proprietary, confidential information belonging to Quintiles (the “Quintiles Confidential Information”).

  

	 	5.3	 Confidentiality Obligations. For the purposes of Sections 5.3 and 5.4, Confidential Information shall mean both Sponsor Confidential
Information and Quintiles Confidential Information. Each party hereunder agrees that Confidential Information disclosed by one party to the other shall be clearly marked ‘confidential’, or if disclosed orally, is confirmed in writing as
having been disclosed as confidential or proprietary of the disclosing party within thirty (30) days after such disclosure. Quintiles and Sponsor each agree that it will only provide Confidential Information to the other party on a need-to-know
basis and to the extent that Confidential Information is required for its undertaking of this Agreement. The Confidential Information shall be used by the receiving party and its employees only for purposes of performing the receiving party’s
obligations hereunder. Except as otherwise expressly authorized in this Agreement, each party agrees that it will not make copies or duplicates of any Confidential Information, or reveal, publish or otherwise disclose the Confidential Information of
the other party to any third party without the prior written consent of the disclosing party. Each party agrees that it will not disclose the terms of this Agreement or any Work Order to any third party without the written consent of the other
party, which shall not unreasonably be withheld. These obligations of confidentiality and nondisclosure shall remain in effect for a period often (10) years after the completion or termination of the applicable Work Order.

  
 3 

	 	5.4	 The foregoing obligations shall not apply to Confidential Information to the extent that it: (a) is or becomes generally available to the
public other than as a result of a disclosure by the receiving party; (b) becomes available to the receiving party on a non-confidential basis from a source which is not prohibited from disclosing such information; (c) was developed
independently of any disclosure by the disclosing party or was known to the receiving party prior to its receipt from the disclosing party, as shown by receiving party’s contemporaneous written evidence; or, (d) is required by law or
regulation to be disclosed, provided that the receiving party shall provide prompt notice of such requirement to the disclosing party to enable the disclosing party to seek a protective order or otherwise prevent or restrict such disclosure.

  

	6.0	 Ownership and Inventions; No Implied Rights. 

 

	 	6.1	 Sponsor’s Property. Sponsor’s property shall mean any invention, trade secret or know-how related to or derived from any materials,
documents, programs or information belonging to Sponsor and supplied to Quintiles pursuant to this Agreement, and such inventions, trade secret and know-how shall remain the exclusive property of Sponsor (collectively “Sponsor’s
Property”). 

  

	 	6.2	 Quintiles’ Property. Any inventions, processes, know-how, trade secrets, improvements, other intellectual properties and other assets,
including but not limited to analytical methods, procedures and techniques, procedure manuals, personnel data, financial information, computer technical expertise and software, which have been developed by Quintiles independent of this Agreement,
which relates to Quintiles’ business or operations, and not falling within Section 6.3a below, shall remain the exclusive property of Quintiles (collectively “Quintiles’ Property”). For the avoidance of doubt,
Quintiles’ Property shall not include any inventions, trade secrets or know-how that incorporates data, information or know-how derived from Sponsor’s Property of Sponsor Confidential Information. 

 

	 	6.3	 Project Intellectual Property (IP). 

  

	 	a)	 Any inventions and discoveries, including any data and information generated or derived by Quintiles as the result of Services performed by
Quintiles under this Agreement and/or uses Sponsor Confidential Information (collectively “Project IP”) are the sole and exclusive property of Sponsor and Quintiles hereby assigns to Sponsor any Quintiles rights to Project IP (including
any patent and all other intellectual property rights therein). Project IP shall be deemed Sponsor Confidential Information for purposes of Section 5.1 above. 

 

	 	b)	 Sponsor and Quintiles agree that any Quintiles’ Property or improvements thereto which are used, improved, modified or developed by Quintiles
under the term of this Agreement, and which do not use or include any Sponsor Confidential Information or Sponsor’s Property, are the sole and exclusive property of Quintiles and shall be deemed Quintiles Confidential Information. To the extent
the Quintiles Software (defined as programs for the purposes of data derivations, population identification, production of statistical analysis outputs, is determined to be necessary to access, retrieve or use the study data

  
 4 

	 	 
generated as a result of the Services performed by Quintiles under this Agreement, Quintiles grants to Sponsor a royalty-free, non-exclusive license with the right use by only Sponsor (and not
its Affiliates or other third parties) without the right to sell, assign or sublicense such software programs and any improvements thereto in connection with such Sponsor project under the Agreement. For such software, Quintiles will provide to
Sponsor the macros. When Quintiles’ Software is no longer necessary to access, retrieve or use the study data as described above, such Quintiles Software shall be returned to Quintiles. 

 

	 	6.4	 No Implied Rights. Except as expressly provided herein, neither party shall have any right, title or interest to or in any patents, patent
applications, know-how (whether patentable or not) or other intellectual property rights of the other party. 

  

	7.0	 Records and Materials. Quintiles agrees to retain all records and data generated in the performance of any Project under this Agreement, and
other Project-related materials including without limitation Sponsor’s proprietary compound (“Records and Materials”), and further agrees to maintain all Records and Materials in a secure area reasonably protected from fire, theft and
destruction. At the completion of the Services by Quintiles, all materials, information and all other data owned by Sponsor, regardless of the method of storage or retrieval, shall be delivered to Sponsor in such form as is then currently in the
possession of Quintiles, subject to the payment obligations set forth in Section 2 herein. Alternatively, at Sponsor’s option and written request, such materials and data may be (i) retained by Quintiles for Sponsor for an agreed-upon
time period, or (ii) disposed of pursuant to the written directions of Sponsor. Sponsor shall pay the costs associated with any of the above options and shall pay a to-be-determined fee for storage by Quintiles of records and materials after
completion or termination of the Services. Quintiles, however, reserves the right to retain, at its own cost and subject to the confidentiality provisions herein, copies of all materials that may be needed to satisfy regulatory requirements or to
resolve disputes regarding the Services. Nothing in this Agreement shall be construed to transfer from Sponsor to Quintiles any FDA or regulatory record-keeping requirements unless such transfer is specifically provided for in the applicable
Transfer of Obligations Form. 

  

	8.0	 Independent Contractor Relationship. For the purposes of this Agreement, the parties hereto are independent contractors and nothing contained
in this Agreement shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers. Neither party shall have the power or right to bind or obligate the other party, and neither party shall
hold itself out as having such authority. 

  

	9.0	 Regulatory Compliance; Certification; Inspections. 

 

	 	9.1	 Quintiles agrees that its Services will be conducted in compliance with all applicable laws, rules and regulations, including but not limited to the
Federal Food, Drug and Cosmetic Act and the regulations promulgated pursuant thereto, and with the standard of care customary in the contract research organization industry. Regarding the FDA’s electronic records and signatures regulation, 21
CFR Part 11 (“Part 11”), Quintiles has a compliance plan in place as to its applicable database applications and electronic records systems and it is working 

  
 5 

	 	 
diligently to implement its plan. Quintiles, however, is not responsible for the compliance or non-compliance of applications or systems used by third parties (including, but not limited to,
investigative sites or third party laboratories), or any Part 11 audits or assessments thereof, unless such applications or systems are owned by Quintiles. Quintiles’ standard operating procedures will be used in performance of the Services,
unless otherwise specifically stated in the Work Order. Sponsor represents that it will cooperate with Quintiles in taking any actions that Quintiles and Sponsor reasonably believes are necessary to comply with the regulatory obligations that have
been transferred to Quintiles hereunder. 

  

	 	9.2	 Quintiles certifies that it has not been debarred under the Generic Drug Enforcement Act and that it will not knowingly employ any person or entity
that has been so debarred to perform any Services under this Agreement. Sponsor represents and certifies that it will not require Quintiles to perform any assignments or tasks in a manner that would violate any applicable law or regulation.

  

	 	9.3	 During the term of this Agreement, Quintiles will permit Sponsor’s representatives (unless such representatives are competitors of Quintiles)
to examine or audit the work performed hereunder and the facilities at which the work is conducted upon reasonable advance notice during regular business hours to determine that the Project assignment is being conducted in accordance with the
relevant Work Order and that the facilities are adequate. Quintiles shall cooperate with Sponsor and allow Sponsor access to relevant records and data to the extent permitted by law. All information (other than Sponsor Confidential Information)
disclosed, revealed to or ascertained by Sponsor in connection with any such audit or examination or in connection with any correspondence between Quintiles and any regulatory authorities (including any FDA Form 483 notices) shall be deemed to
constitute Quintiles Confidential Information for purposes of this Agreement. Sponsor shall reimburse Quintiles for its time and reasonable expenses associated with any such audit by Sponsor, unless such audit finds that Quintiles breached this
Agreement or any applicable law or regulation. 

  

	 	9.4	 If any governmental or regulatory agency conducts, or gives notice to Quintiles of its intent to conduct an inspection or to take any regulatory
action with respect to any Project or Services pursuant to this Agreement, Quintiles will promptly notify Sponsor prior to complying with such request. Where reasonably practicable, Sponsor will be given the opportunity to have a representative
present during any governmental or regulatory inspection. Sponsor shall reimburse Quintiles for its time and reasonable expenses (including reasonable attorney fees and the costs of responding to findings) associated with any such inspection, unless
such inspection finds that Quintiles breached this Agreement or any applicable law or regulation. 

  

	10.0	 Conflict of Agreements. Quintiles represents to Sponsor that it is not a party to any agreement which would prevent it from fulfilling its
obligations under this Agreement and that during the term of this Agreement, Quintiles agrees that it will not enter into any agreement to provide services which would in any way prevent it from providing the Services contemplated under this
Agreement. 

  
 6 

	11.0	 Publication; Use of Name. Project data or results may not be published or referred to, in whole or in part, by Quintiles or its affiliates
without the prior expressed written consent of Sponsor. Neither party will use the other party’s name in connection with any publication or promotion without the other party’s prior, written consent. 

 

	12.0	 Limitation of Liability. Neither Quintiles, nor its affiliates, nor any of Quintiles’ or its affiliate’s directors, officers,
employees, subcontractors or agents shall have any liability of any type (including, but not limited to, contract, negligence, and tort liability), for any loss of profits, opportunity or goodwill, or any type of special, incidental, indirect or
consequential damage or loss in connection with or arising out of this Agreement, any Work Order, or the Services performed by Quintiles hereunder. In addition, in no event shall the collective, aggregate liability (including, but not limited to,
contract, negligence and tort liability) of Quintiles or its affiliates, or Quintiles’ or its affiliates’ directors, officers, employees, subcontractors and agents, under this Agreement or any Work Order hereunder exceed the amount of fees
actually received by Quintiles from Sponsor for the assignment or task from which such liability arose. 

 EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE OR NON-INFRINGEMENT OF A PATENT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHT. 
  

	13.0	 Indemnification. Sponsor shall indemnify, defend and hold harmless Quintiles and its affiliates, and its and their directors, officers,
employees and agents (each, a “Quintiles Indemnified Party”), from and against any and all losses, damages, liabilities, reasonable attorney fees, court costs, and expenses (collectively “Losses”), joint or several, resulting or
arising from any third-party claims, actions, proceedings, investigations or litigation relating to or arising from or in connection with this Agreement, any Work Order, or the Services contemplated herein (including, without limitation, any Losses
arising from or in connection with any study, test, device, product or potential product to which this Agreement or any Work Order relates), except to the extent such Losses are determined to have resulted solely from the negligence or intentional
misconduct of a Quintiles Indemnified Party seeking indemnity hereunder. Quintiles shall indemnify and hold harmless Sponsor, its affiliates and their respective directors, officers, employees and agents harmless from and against any Losses arising
from the negligence or intentional misconduct of a Quintiles Indemnified Party. 

  

	14.0	 Indemnification Procedure. Any party seeking indemnity hereunder shall (a) give prompt notice to the other party (the “Indemnifying
Party”) of any such claim or lawsuit (including a copy thereof) served upon it, (b) permit the Indemnifying Party to assume full responsibility to investigate, prepare for, and defend against such claim or lawsuit, (c) shall fully
cooperate with the Indemnifying Party and its legal representatives in the investigation of any matter the subject of indemnification, and (d) shall not compromise or settle such claim or lawsuit in a manner that adversely affects the other
party’s rights under this Agreement without the Indemnifying Party’s prior written consent. The party 

  
 7 

	 	 
seeking indemnity shall not unreasonably withhold its approval of the settlement of any claim, liability, or action covered by this Indemnification provision. 

 

	15.0	 Termination. 

  

	 	15.1	 Sponsor may terminate this Agreement or any Work Order without cause at any time during the term of the Agreement on thirty (30) day’s
prior written notice to Quintiles. 

  

	 	15.2	 Either party may terminate this Agreement or any Work Order for material breach upon thirty (30) days’ written notice specifying the
nature of the breach, if such breach has not been substantially cured within the thirty (30) day period. During the 30-day cure period for termination due to breach, each party will continue to perform its obligations under the Agreement. If
the cure period has expired without a substantial cure of the breach, then the parties shall promptly meet to prepare a close-out schedule, and Quintiles shall cease performing all work not necessary for the orderly close-out of the Services or
required by laws or regulations. 

  

	 	15.3	 Either party may terminate this Agreement or any Work Orders immediately upon provision of written notice if the other party becomes insolvent or
files for bankruptcy. Any written termination notice shall identify the specific Work Order or Work Orders that are being terminated. 

  

	 	15.4	 If this Agreement or any Work Order is terminated for reasons other than material breach by Quintiles, Sponsor shall pay Quintiles for all Services
properly performed in accordance with any applicable Work Order and reimburse Quintiles for all reasonable costs and expenses incurred in performing such Services, including all non-cancelable costs incurred prior to the termination date. If
payments are unit or milestone based, and the Agreement or a Work Order is terminated after costs have been incurred toward achieving portions of one or more incomplete units or milestones, Sponsor will pay Quintiles’ standard fees for actual
work performed toward those incomplete units or milestones up to the date of termination (not to exceed the actual amount due for completion of such milestone or unit), in addition to paying for completed units or milestones.

  

	 	15.5	 Upon receipt of a termination notice, Quintiles shall promptly cease performing any work not necessary for the orderly close out of the affected
Project(s), or for the fulfillment of any regulatory requirements, and will submit an itemized accounting of the Services completed, expenses incurred pursuant to the performance of the Services, any non-cancelable expenses incurred relating to the
unfinished Work Order, and payments received in order to determine a balance to be paid by either party to the other. Such balance will be paid within thirty (30) days of receipt of such itemized accounting. 

  
 8 

	16.0	 Relationship with Affiliates; Subcontracts. 

 

	 	16.1	 Sponsor agrees that Quintiles may use the Services of its corporate affiliates to fulfill Quintiles’ obligations under this Agreement and any
Work Order. Any affiliate so used shall be subject to all of the terms and conditions applicable to Quintiles under this Agreement or any Work Order, and entitled to all rights and protections afforded Quintiles under this Agreement and any Work
Order. Quintiles agrees that Sponsor’s affiliates may use the services of Quintiles (and its affiliates) under this Agreement. In such event, such Sponsor’s affiliates shall be bound by all the terms and conditions of this Agreement and
any Work Order and entitled to all rights and protections afforded Sponsor under this Agreement and any Work Order. Any such affiliate of Sponsor or Quintiles may execute a Work Order directly. The term “affiliate” shall mean all entities
controlling, controlled by or under common control with Sponsor or Quintiles, as the case may be. The term “control” shall mean the ability to vote fifty percent (50%) or more of the voting securities of any entity or otherwise having
the ability to influence and direct the polices and direction of an entity. 

  

	 	16.2	 Quintiles shall have the right to subcontract a portion of its obligations in connection with its performance of any Project (other than to its
corporate affiliates), provided that (i) Quintiles shall have obtained the prior written approval of Sponsor to the subcontract, including providing Sponsor with sufficient information to enable proper evaluation of such subcontractor;
(ii) such subcontract shall not relieve Quintiles of any of its obligations under this Agreement; (iii) Quintiles shall enter into a written agreement with each subcontractor on terms and conditions consistent with this Agreement,
including for the benefit of Sponsor, provisions substantially similar to those of Sections 5.0,6.0, and 11.0; (iv) each Work Order, when appropriate, shall specify the name of such subcontractors; and (v) if requested by Sponsor,
Quintiles agrees to provide Sponsor with a copy of each such subcontract. 

  

	17.0	 Cooperation; Delays; Disclosure of Hazards. 

 

	 	17.1	 Sponsor shall forward to Quintiles in a timely manner all documents, materials and information in Sponsor’s possession or control necessary for
Quintiles to conduct the Services. Quintiles will use commercially reasonable efforts to complete the agreed upon Services within the timelines set forth in an executed Work Order or Change Order. Quintiles shall not be liable to Sponsor nor be
deemed to have breached this Agreement for errors, delays or other consequences arising from Sponsor’s failure to timely provide documents, materials or information or to otherwise cooperate with Quintiles in order for Quintiles to timely and
properly perform its obligations under the relevant Work Order or Change Order. 

  

	 	17.2	 Quintiles and Sponsor agree to notify the other in writing immediately if any delays or limits are encountered in their performance of any Work
Order, and shall use good faith efforts to negotiate an acceptable resolution to such delays or limits. 

  
 9 

	 	17.3	 Sponsor shall provide Quintiles with all information available to it regarding known or potential hazards associated with the use of any substances
supplied to Quintiles by Sponsor, and Sponsor shall comply with all current legislation and regulations concerning the shipment of substances by the land, sea or air. Quintiles agrees to comply with all laws, rules and regulations, including written
instructions provided by Sponsor, relating to the storage and handling of any such substances received from Sponsor. 

  

	18.0	 Force Majeure. In the event either party shall be delayed or hindered in or prevented from the performance of any act required hereunder by
reasons of strike, lockouts, labor troubles, inability to procure materials or services, failure of power or restrictive government or judicial orders, or decrees, riots, insurrection, war, Acts of God, inclement weather or other reason or cause
beyond that party’s control, then performance of such act (except for the payment of money owed) shall be excused for the period of such delay. 

  

	19.0	 Notices and Deliveries. Any notice required or permitted to be given hereunder by either party hereunder shall be in writing and shall be
deemed given on the date received if delivered personally or by a reputable overnight delivery service, or three (3) days after the date postmarked if sent by registered or certified mail, return receipt requested, postage prepaid to the
following addresses: 

  

											
	If to Quintiles:	  	If to Sponsor:
		 	Quintiles, Inc.	  		 	Sunesis Pharmaceuticals, Inc.
		 	10245 Hickman Mills Drive	  		 	341 Oyster Point Boulevard
		 	Kansas City, MO 64137	  		 	South San Francisco, CA 94080
		 	Attn:  	 	Michael J. Baltezor, Ph.D.	  		 	Attn:  	 	Daryl B. Winter, Ph.D.
		 		 	General Manager	  		 		 	SVP, General Counsel

 If
Sponsor delivers, ships, or mails materials or documents to Quintiles, or requests that Quintiles deliver, ship, or mail materials or documents to Sponsor or to third parties, then the expense and risk of loss for such deliveries, shipments, or
mailings shall be borne by Sponsor. Quintiles disclaims any liability for the actions or omissions of third-party delivery services or carriers. 
  

	20.0	 Insurance. During the term of this Agreement to cover its obligations hereunder, each party shall maintain insurance coverage as follows: 1)
(a) Professional Liability for Quintiles in an amount of at least US$10,000,000.00; (b) Product Liability for Sponsor in an amount of at least US$10,000,000.00; and 2) General Liability in amounts of at least US$3,000,000.00. All insurance
amounts may be obtained by full, individual primary policy amount; a primary amount of less than minimum requirement enhanced by a blanket excess umbrella policy; or a combination of either. Each party shall provide the other party with a
certificate of insurance upon request. The insured shall provide the other party with at least thirty (30) days prior written notice of any material change, cancellation or expiration of the above-required insurance.

  
 10 

	21.0	 Foreign Currency Exchange. The currency to be used for invoice and payment shall be the currency stated in the Budget or Table attached to
the Work Order (the “Contracted Currency”). If Quintiles incurs pass-through costs in a currency other than the Contracted Currency, then Sponsor shall reimburse Quintiles for Quintiles’ actual costs in the Contracted Currency based
on the Oanda foreign currency exchange rate (Oanda.com) for the applicable currencies on the last business Friday of the month. For Work Orders that involve the performance of Services by Quintiles or its affiliates in any countries that use
currencies other than the Contracted Currency, and the fees for such Services will exceed $500,000, then a currency exchange provision shall be included in the Work Order. 

 

	22.0	 Inflation Adjustments. Where services in a Work Order are provided by Quintiles over multiple calendar years, Quintiles may increase its fees
at the beginning of each calendar year to reflect increases in Quintiles’ business costs on a prospective basis only. Quintiles’ overall costs may be increased for the next twelve (12) month period using four percent (4%) or the
average percentage change in the wages/earnings survey as published in the Economist (or as reported at www.economist.com) or the equivalent inflation index of the country where services are performed, over the preceding twelve
(12) month period. 

  

	23.0	 Binding Agreement and Assignment. This Agreement shall be binding upon and inure to the benefit of Sponsor and Quintiles and their respective
successors and permitted assigns. Except as stated above in Section 17.1, neither party may assign any of its rights or obligations under this Agreement to any party without the express, written consent of the other party.

  

	24.0	 Choice of Law, Waiver and Enforceability. This Agreement shall be construed, governed, interpreted, and applied in accordance with the laws
of the State of New York exclusive of its conflicts of law provisions. The failure to enforce any right or provision herein shall not constitute a waiver of that right or provision. Any waiver of a breach of a provision shall not constitute a waiver
of any subsequent breach of that provision. If any provisions herein are found to be unenforceable on the grounds that they are overly broad or in conflict with applicable laws, it is the intent of the parties that such provisions be replaced,
reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and that the remaining provisions shall not in any way be affected or impaired thereby. 

 

	25.0	 Survival. The rights and obligations of Sponsor and Quintiles, which by intent or meaning have validity beyond such termination (including,
but not limited to, rights with respect to inventions, confidentiality, publication, discoveries and improvements, indemnification and liability limitations) shall survive the termination of this Agreement or any Work Order.

  

	26.0	 Arbitration. Any controversy or claim arising out of or relating to this Agreement or the breach thereof shall be settled by arbitration
administered by the American Arbitration Association (“AAA”) under its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator shall be binding and may be entered in any court having jurisdiction thereof. Such
arbitration shall be filed and conducted at the office of the AAA closest to the Quintiles office having responsibility for the Project, and shall be 

  
 11 

	 	 
conducted in English by one arbitrator mutually acceptable to the parties selected in accordance with AAA Rules. The arbitrator shall not have the power to award any punitive damages or any
damages excluded by this Agreement. 

  

	27.0	 Entire Agreement, Headings and Modification. This Agreement, together with the applicable Work Orders, contains the entire understandings of
the parties with respect to the subject matter herein, and supersedes all previous agreements (oral and written), negotiations and discussions. The descriptive headings of the sections of this Agreement are inserted for convenience only and shall
not control or affect the meaning or construction of any provision hereof. Any modifications to the provisions herein must be in writing and signed by the parties. 

IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto through their duly authorized officers on the
date(s) set forth below. 
 ACKNOWLEDGED, ACCEPTED AND AGREED TO: 

 

									
	Quintiles, Inc.	 		 	 Sunesis Pharmaceuticals, Inc.

									
					
	By:	 	 /s/ Michael J. Baltezor Ph.D.
	 		 	 By:	 	 /s/ Daryl B. Winter, Ph.D.

		 	(signature)	 		 		 	(signature)

									
					
	Print Name:	 	 Michael J. Baltezor, Ph.D.
	 		 	Print Name:	 	 Daryl B. Winter, Ph.D.

									
					
	Title:	 	 General Manager
	 		 	Title:	 	 Senior Vice President & General
Counsel

									
					
	Date:	 	 August 26, 2004
	 		 	Date:	 	 8/23/04

 FEDERAL ID # 56-1323952 

  
 12 

 EXHIBIT A 
 SAMPLE WORK ORDER 
 WORK ORDER 

This Work Order (“Work Order”) is between
                                 (“Sponsor”) and
                                 (“Quintiles”) and relates to the Master
Services Agreement dated                     , (the “Master Agreement”), which is incorporated by reference herein. Pursuant to the
Master Agreement, Quintiles has agreed to perform certain services in accordance with written work orders, such as this one, entered into from time-to-time. 
 The parties hereby agree as follows: 
 1. Work Order. This
document constitutes a “Work Order” under the Master Agreement and this Work Order and the services contemplated herein are subject to the terms and provisions of the Master Agreement. 

2. Services and Payment of Fees and Expenses. The specific services contemplated by this Work Order (the
“Services”) and the related payment terms and obligations are set forth on the following attachments, which are incorporated herein by reference: 
  

							
		 	SCOPE OF WORK	  	ATTACHMENT	 	 1

		 	PROJECT BUDGET	  	ATTACHMENT	 	 2

		 	TIMELINE	  	ATTACHMENT	 	 3

		 	PAYMENT SCHEDULE	  	ATTACHMENT	 	 4

		 	TRANSFER OF OBLIGATIONS	 	
		 	(if applicable)	  	ATTACHMENT 	 	 5

		 	LOCAL REPRESENTATIVE DUTIES	 	
		 	(if applicable)	  	ATTACHMENT 	 	 6

 To the extent that any terms and provisions in any of the attachments hereto conflict with the Master Agreement and this Work Order, the terms and provisions of the Master Agreement and this Task Order
shall control. 
 3. Term. The term of this Work Order shall commence on the date of execution and shall
continue until the services described in Attachment 1 are completed, unless this Work Order is terminated in accordance with the Master Agreement. If the Master Agreement is terminated or expires, but this Work Order is not terminated or
completed, then the terms of the Master Agreement shall continue to apply to this Work Order until the Work Order is either terminated or completed. 
 4. Affiliates and Subcontractors. Sponsor agrees that Quintiles may use the services of its corporate affiliates to fulfill Quintiles’ obligations under this Work Order. Any such affiliates
shall be bound by all the terms and conditions of, and be entitled to all rights and protections afforded under, the Master Agreement and this Work Order. Any subcontractors or consultants (other than Quintiles’ affiliates) that will be used by
Quintiles in performing the Services are listed below: 

  
 13 

 [Insert names of any subcontractors or consultants, other than
Quintiles’ affiliates, that will be used] 
 5. Amendments. No modification, amendment, or
waiver of this Work Order shall be effective unless in writing and duly executed and delivered by each party to the other. 
 6. Currency Exchange. [Insert currency exchange provision in all Work Orders in which Quintiles will earn fees or incur expenses in excess of one million US. Dollars in a currency differing from
the invoice and payment currency] 
 7. Inflation and Cost Adjustment. [Insert cost adjustment
provision and inflation provision, if appropriate.] 
 ACKNOWLEDGED, ACCEPTED AND AGREED TO: 

 

									
	[Quintiles]	 		 	[Sponsor]
					
	By:	 	  
	 		 	By:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]